Literature DB >> 33659259

Immunological Endotyping of Chronic Critical Illness After Severe Sepsis.

Brittany P Fenner1, D B Darden1, Lauren S Kelly1, Jaimar Rincon1, Scott C Brakenridge1, Shawn D Larson1, Frederick A Moore1, Philip A Efron1, Lyle L Moldawer1.   

Abstract

Improved management of severe sepsis has been one of the major health care accomplishments of the last two decades. Due to enhanced recognition and improved management of severe sepsis, in-hospital mortality has been reduced by up to 40%. With that good news, a new syndrome has unfortunately replaced in-hospital multi-organ failure and death. This syndrome of chronic critical illness (CCI) includes sepsis patients who survive the early "cytokine or genomic storm," but fail to fully recover, and progress into a persistent state of manageable organ injury requiring prolonged intensive care. These patients are commonly discharged to long-term care facilities where sepsis recidivism is high. As many as 33% of sepsis survivors develop CCI. CCI is the result, at least in part, of a maladaptive host response to chronic pattern-recognition receptor (PRR)-mediated processes. This maladaptive response results in dysregulated myelopoiesis, chronic inflammation, T-cell atrophy, T-cell exhaustion, and the expansion of suppressor cell functions. We have defined this panoply of host responses as a persistent inflammatory, immune suppressive and protein catabolic syndrome (PICS). Why is this important? We propose that PICS in survivors of critical illness is its own common, unique immunological endotype driven by the constant release of organ injury-associated, endogenous alarmins, and microbial products from secondary infections. While this syndrome can develop as a result of a diverse set of pathologies, it represents a shared outcome with a unique underlying pathobiological mechanism. Despite being a common outcome, there are no therapeutic interventions other than supportive therapies for this common disorder. Only through an improved understanding of the immunological endotype of PICS can rational therapeutic interventions be designed.
Copyright © 2021 Fenner, Darden, Kelly, Rincon, Brakenridge, Larson, Moore, Efron and Moldawer.

Entities:  

Keywords:  PICS; acute kidney injury; aging; immunosuppression; inflammation

Year:  2021        PMID: 33659259      PMCID: PMC7917137          DOI: 10.3389/fmed.2020.616694

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  5 in total

1.  Biomarker Evidence of the Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) in Chronic Critical Illness (CCI) After Surgical Sepsis.

Authors:  Dijoia B Darden; Scott C Brakenridge; Philip A Efron; Gabriela L Ghita; Brittany P Fenner; Lauren S Kelly; Alicia M Mohr; Lyle L Moldawer; Frederick A Moore
Journal:  Ann Surg       Date:  2021-10-01       Impact factor: 13.787

2.  N6-methyladenosine (m6A) methyltransferase METTL3 regulates sepsis-induced myocardial injury through IGF2BP1/HDAC4 dependent manner.

Authors:  Hao Shen; Keliang Xie; Miaomiao Li; Qianyu Yang; Xiaoye Wang
Journal:  Cell Death Discov       Date:  2022-07-15

Review 3.  Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19.

Authors:  Ivo Udovicic; Ivan Stanojevic; Dragan Djordjevic; Snjezana Zeba; Goran Rondovic; Tanja Abazovic; Srdjan Lazic; Danilo Vojvodic; Kendrick To; Dzihan Abazovic; Wasim Khan; Maja Surbatovic
Journal:  J Clin Med       Date:  2021-12-12       Impact factor: 4.241

4.  Long Noncoding RNA ZFAS1 Protects HK-2 Cells against Sepsis-Induced Injury through Targeting the miR3723p/PPARα Axis.

Authors:  Bingchang Hei; Caifang Yue; Yao Sun
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

5.  A Novel Single Cell RNA-seq Analysis of Non-Myeloid Circulating Cells in Late Sepsis.

Authors:  Dijoia B Darden; Xiaoru Dong; Maigan A Brusko; Lauren Kelly; Brittany Fenner; Jaimar C Rincon; Marvin L Dirain; Ricardo Ungaro; Dina C Nacionales; Marie Gauthier; Michael Kladde; Todd M Brusko; Azra Bihorac; Frederick A Moore; Tyler Loftus; Rhonda Bacher; Lyle L Moldawer; Alicia M Mohr; Philip A Efron
Journal:  Front Immunol       Date:  2021-08-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.